GlassScriptPhysician profile
Jeffrey Bruss
NPI 1942290309
$1,820.99
in general payments reported to CMS, 2019-2025
24 companies · $395 in 2025
The $395 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $145 · 2021: $73.69 · 2022: $228 · 2023: $199 · 2024: $508 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,101.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $279.86 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $215.48 | 2019-2024 | Xarelto |
| Shockwave Medical, INC | $158.96 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $138.73 | 2019-2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $135.50 | 2020-2025 | Lifevest |
| Abiomed | $127.87 | 2019-2021 | |
| Boston Scientific Corporation | $87.09 | 2023-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Cvrx, INC. | $81.46 | 2024-2025 | Barostim Neo System |
| Bardy Diagnostics, INC. | $77.33 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $73.99 | 2024-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $60.73 | 2022-2023 | Jot Dx |
| Astrazeneca Pharmaceuticals LP | $51.90 | 2022-2024 | Farxiga, Wainua |
| Irhythm Technologies, INC. | $44.28 | 2024 | Zio Xt Patch, Zio Monitor |
| Regeneron Healthcare Solutions, INC. | $42.47 | 2025 | Evkeeza |
| Kestra Medical Technology Services, INC. | $41.20 | 2023-2024 | Assure Wcd |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $38.17 | 2023-2025 | Verquvo |
| Medtronic Vascular, INC. | $28.85 | 2019 | |
| Alnylam Pharmaceuticals INC. | $25.15 | 2022 | |
| Cardiovascular Systems INC. | $23.46 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.03 | 2020 | |
| Sanofi-Aventis U.S. LLC | $19.06 | 2019 | |
| Altathera Pharmaceuticals LLC | $17.48 | 2025 | Sotalol Hydrochloride |
| Scpharmaceuticals INC. | $16.70 | 2025 | |
| Getinge USA Sales, LLC | $14.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Bruss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.